Subject(s)
Bone Neoplasms/diagnostic imaging , Heart Neoplasms/diagnostic imaging , Lymphoma, Large B-Cell, Diffuse/diagnostic imaging , Mediastinal Neoplasms/diagnostic imaging , Peripheral Nervous System Neoplasms/diagnostic imaging , Aged, 80 and over , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/drug therapy , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Fluorodeoxyglucose F18 , Heart Neoplasms/drug therapy , Humans , Lymph Nodes , Lymphoma, Large B-Cell, Diffuse/drug therapy , Mediastinal Neoplasms/drug therapy , Positron Emission Tomography Computed Tomography , Prednisone/therapeutic use , Radiopharmaceuticals , Rituximab , Vincristine/therapeutic useSubject(s)
Cardiomyopathies/diagnostic imaging , Positron-Emission Tomography , Sarcoidosis/diagnostic imaging , Adult , Cardiac Imaging Techniques , Clinical Protocols , Diet, Carbohydrate-Restricted , Diet, High-Fat , Female , Fluorodeoxyglucose F18 , Humans , Middle Aged , Multimodal Imaging , Radiopharmaceuticals , Tomography, X-Ray ComputedABSTRACT
Osseous metastatic disease from malignancy is a common occurrence with significant patient morbidity and mortality as well as increasing health care expenditures. Patient management plans frequently change with the identification of skeletal metastasis and the upstaging of disease status. Bone scintigraphy remains the current mainstay of diagnostic imaging procedures in nuclear medicine for the early detection of skeletal metastasis owing to their high sensitivity. Emerging positron tracers and the increasing use and availability of hybrid single-photon emission computed tomography and positron emission tomography (PET)/computed tomography machines enable physicians to diagnose metastatic disease in bones with superior accuracy. This review introduces the basics of PET and the commonly used positron tracers used to evaluate skeletal metastases.
Subject(s)
Bone Neoplasms/diagnosis , Bone Neoplasms/secondary , Positron-Emission Tomography/methods , Tomography, X-Ray Computed/methods , Breast Neoplasms/pathology , Carcinoma, Neuroendocrine/pathology , Female , History, Ancient , Humans , Kidney Neoplasms/pathology , Lung Neoplasms/pathology , Magnetic Resonance Imaging , Male , Multiple Myeloma/pathology , Prostatic Neoplasms/pathology , Thyroid Neoplasms/pathologyABSTRACT
OBJECTIVE: 2-deoxy-2-[¹8F]fluoro-D-glucose positron emission tomography/computed tomography ([¹8F] FDG PET/CT) has become an established imaging tool in oncology and is now emerging in the field of infectious disease. The aim of this study is to assess the value of fluorine [¹8F] FDG PET/CT in the investigation of patients with fever of unknown origin (FUO). METHODS: [¹8F] FDG PET/CT scans and clinical data of 12 patients were reviewed. These patients met the revised definition criteria of FUO (febrile illness of greater than 3 weeks duration, temperature greater than 38.3°C and no diagnosis after at least 3 days of in-patient investigation or 2 weeks of outpatient investigation). A retrospective analysis of our local database was performed and evaluated for the diagnostic contribution of [¹8F] FDG PET/CT scans. RESULTS: An infective cause of the FUO was found in four (33.3%) patients, a neoplasm in two (16.7%) patients, non-infectious inflammatory disease or autoimmune in one (8.3%) patient. A definitive causative agent could not be found in five (41.7%) patients despite extensive investigations.In all, five (41.6%) patients had a PET/CT scan that was abnormal and was deemed 'helpful' as part of the investigation that pointed to the final diagnosis. Two (16.7%) patients had abnormal scans, which were deemed 'not-helpful' for the final diagnosis. CONCLUSION: [¹8F] FDG PET/CT can be helpful in some patients with FUO. This study adds value to the limited data published so far on this subject.